ANAC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANAC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
For the three months ended in Mar. 2016, Anacor Pharmaceuticals's Net Income From Continuing Operations was $-16.15 Mil. Its Depreciation, Depletion and Amortization was $0.19 Mil. Its Change In Working Capital was $0.03 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $5.33 Mil. And its Cash Flow from Others was $1.01 Mil. In all, Anacor Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2016 was $-9.59 Mil.
The historical data trend for Anacor Pharmaceuticals's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anacor Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Cash Flow from Operations | Get a 7-Day Free Trial | -35.70 | -54.94 | 90.08 | -39.32 | -56.27 |
Anacor Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | |
Cash Flow from Operations | Get a 7-Day Free Trial | 5.68 | -23.75 | -24.22 | -13.99 | -9.59 |
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Anacor Pharmaceuticals's Cash Flow from Operations for the fiscal year that ended in Dec. 2015 is calculated as:
Cash Flow from Operations | (A: Dec. 2015 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | -61.248 | + | 0.629 | + | -19.065 | + | 0 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 0 | + | 18.48 | + | 4.932 |
= | -56.27 |
Anacor Pharmaceuticals's Cash Flow from Operations for the quarter that ended in Mar. 2016 is:
Cash Flow from Operations | (Q: Mar. 2016 ) | ||||||
= | Net Income From Continuing Operations | + | Depreciation, Depletion and Amortization | + | Change In Working Capital | + | Deferred Tax |
= | -16.147 | + | 0.192 | + | 0.028 | + | 0 |
+ | Cash from Discontinued Operating Activities | + | Asset Impairment Charge | + | Stock Based Compensation | + | Cash Flow from Others |
+ | 0 | + | 0 | + | 5.33 | + | 1.009 |
= | -9.59 |
Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anacor Pharmaceuticals (NAS:ANAC) Cash Flow from Operations Explanation
For companies reported in indirect method, cash flow from operations contains six items:
1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Anacor Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2016 was $-16.15 Mil.
2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets
Anacor Pharmaceuticals's depreciation, depletion and amortization for the three months ended in Mar. 2016 was $0.19 Mil.
3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.
Anacor Pharmaceuticals's change in working capital for the three months ended in Mar. 2016 was $0.03 Mil. It means Anacor Pharmaceuticals's working capital increased by $0.03 Mil from Dec. 2015 to Mar. 2016 .
4. Deferred Tax:
It is the cash flow generated from deferred tax.
Anacor Pharmaceuticals's cash flow from deferred tax for the three months ended in Mar. 2016 was $0.00 Mil.
5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.
Anacor Pharmaceuticals's cash from discontinued operating Activities for the three months ended in Mar. 2016 was $0.00 Mil.
6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.
Anacor Pharmaceuticals's asset impairment charge for the three months ended in Mar. 2016 was $0.00 Mil.
7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.
Anacor Pharmaceuticals's stock based compensation for the three months ended in Mar. 2016 was $5.33 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).
Anacor Pharmaceuticals's cash flow from others for the three months ended in Mar. 2016 was $1.01 Mil.
Thank you for viewing the detailed overview of Anacor Pharmaceuticals's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.
Keith R Leonard | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
William Jl Rieflin | director | NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Anders D Hove | director | 30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112 |
Lucy Shapiro | director | 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121 |
Graeme Bell | officer: Executive VP and CFO | 1324 WAVERLY ROAD, GLADWYNE PA 19035 |
Ryan T Sullivan | officer: EVP and General Counsel | C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855 |
Wendall Wierenga | director | 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
Paul L Berns | director, officer: President and CEO | 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
Mark Leschly | director | RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019 |
Geoffrey M. Parker | officer: Executive Vice President & CFO | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Paul H Klingenstein | director | 428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
David P Perry | director, officer: President and CEO | 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
Rho Management Ventures Iv Llc | 10 percent owner | 124 DUNE RD, QUOGUE NY 11959 |
Rho Ventures Iv Qp Lp | 10 percent owner | 124 DUNE RD, QUOGUE NY 11959 |
Rho Ventures Iv Lp | 10 percent owner | 124 DUNE ROAD, QUOGUE NY 11959 |
From GuruFocus
By Business Wire Business Wire • 02-10-2023
By Business Wire Business Wire • 06-02-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.